NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) released the comprehensive findings from the ROSE2 Phase 2 clinical trial, which examined the efficacy of obicetrapib, their oral, low-dose cholesteryl ester transfer protein inhibitor, in conjunction with ezetimibe as an adjunct to high-intensity statin therapy. 

According to NewAmsterdam, the trial successfully met both primary and secondary endpoints, revealing statistically significant and clinically meaningful reductions in LDL-C and apolipoprotein B. Notably, the combination of Obicetrapib and Ezetimibe demonstrated exceptional results, with 87.1% of patients achieving the guideline-recommended LDL-C goal of <55 mg/dL, compared to 0% of patients on placebo. The trial also showcased promising improvements in various lipid and lipoprotein parameters that are indicative of cardiovascular disease risk, such as LDL particles and Lipoprotein(a). The treatment was well-tolerated, exhibiting favorable safety profiles. 

On Friday, $NAMS closed at $13.77, experiencing a slight decline of $0.02 (-0.11%).

Acrivon Therapeutics, Inc. (Nasdaq: ACRV), a biopharmaceutical company, received an "Outperform" rating with a price target of $25 from Oppenheimer. 

With a closing price of $12.37 on Friday, this indicates a potential upside of $12.63 (102.06%) for $ACRV, based on the brokerage firm's view.

Veeva Systems Inc. (NYSE: VEEV), a leading provider of cloud-based software for the life sciences industry, had its price target increased from $185 to $210 by Keybanc.

Ending the week at $195.00, this adjustment suggests a potential upside of $15.00 (7.69%) for $VEEV, according to the investment firm's analysis.

Amprius Technologies, Inc. (NYSE: AMPX), a company specializing in advanced lithium-ion batteries, was initiated with an "Outperform" rating and a price target of $16 by Northland Capital. 

With Friday's closing price at $7.65, this adjustment implies a potential upside of $8.35 (109.15%) for $AMPX, as per the analyst's view.

It is important to note that the potential upsides mentioned above are based on the perspectives of the respective brokerage firm, investment firm, or analysts. These estimates should be considered in conjunction with market fluctuations and individual investment decisions.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)